Status:
RECRUITING
Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction
Lead Sponsor:
Shanghai Tong Ren Hospital
Collaborating Sponsors:
China Cardiovascular Association
Conditions:
Acute Myocardial Infarction
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
This is a multi-center, prospective, randomized, controlled study. The patients with STEMI who were to undergo PPCI were divided into PCSK9 inhibitor group (n=80) and conventional treatment group (n=8...
Eligibility Criteria
Inclusion
- The age is greater than 18 years old and less than or equal to 80 years old.
- Patients who are clinically diagnosed with STEMI onset within 24 hours and who are planning to undergo PPCI .
- Signed informed consent.
Exclusion
- Patients who are allergic to PCSK9 inhibitors.
- Multivessel disease planned for selective intervention within half a year.
- Patients who have previously undergone revascularization.
- Pregnant women or women who plan to become pregnant in the next 2 years.
- Patients whose life expectancy is less than 1 year.
- Severe liver or kidney dysfunction (ALT\>5 times ULA, eGFR\<15ml/min/1.73m2)
- Known active malignant tumor diseases.
- Patients considered by the investigator to be unsuitable to participate in this study.
Key Trial Info
Start Date :
October 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT05292404
Start Date
October 1 2022
End Date
December 1 2025
Last Update
December 20 2024
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
nineth people's hospital, School of Medicine, shanghai jiaotong university
Shanghai, Shanghai Municipality, China, 200050
2
Shanghai chest hospital
Shanghai, Shanghai Municipality, China, 200050
3
Shanghai tongren hospital
Shanghai, Shanghai Municipality, China, 200050
4
tenth people's hospital, tongji university, Shanghai
Shanghai, Shanghai Municipality, China, 200050